Company Overview

PRIME exits® and American HealthCare Capital are pleased to exclusively present a high-performing clinical research site for sale specializing in pharmaceutical, biotechnology, medical device, and diagnostic clinical trials. The Company operates a full-service research model, supporting Phase II through Phase IV studies across a broad range of therapeutic areas.Since inception, the Company has been awarded more than 70 clinical trials, reflecting strong sponsor confidence and consistent execution. The business operates within a clinical care setting, providing direct access to a high-volume patient population. This structure supports efficient patient identification and enrollment, with the majority of participants sourced internally.

Sponsors and Studies

The Company maintains relationships with a diversified base of over 15 pharmaceutical sponsors and CROs, supporting a consistent flow of clinical trial activity across multiple therapeutic areas.The Company is currently engaged in more than 20 active clinical studies and maintains a strong pipeline, with approximately $1.5 million of revenue expected from signed studies over the next 12 months.

Financial Overview

The Company generated approximately $1.4 million in revenue and over $600,000 in net income in 2025, with continued growth expected. Revenue is projected to reach approximately $2.0 million in 2026 with an improved profit margin and a majority of business already under contract.

Exit Strategy

All existing staff are expected to stay on post-acquisition. Ownership is seeking a strategic partner to support expansion and scale the platform. Ownership is willing to remain involved to support transition and future growth.

Asking Price

The asking price for this opportunity is $6 million, excluding cash and receivables.